Treatment of EGFR mutant advanced NSCLC

Raffaele Califano

Department of Medical Oncology
The Christie and Manchester University Hospital
Manchester, UK
DISCLOSURE INFORMATION
RAFFAELE CALIFANO

Honoraria and consultancy fees: AstraZeneca, Boeringher Ingelheim, Lilly Oncology, Roche, Pfizer, MSD, Bristol Myers Squibb, Takeda and Novartis

Grants paid to Institution for conduct of clinical trials or contracted research: Roche, AstraZeneca, Pfizer, Clovis, Lilly Oncology, MSD, BMS, Abbvie, Takeda and Novartis

Stock Ownership: The Christie Private Care

Non-remunerated activities: Principal investigator for trials with Roche, AstraZeneca, Pfizer, Clovis, Lilly Oncology, MSD, BMS, Abbvie, Takeda and Novartis

Leadership roles (non remunerated): ESMO

Other non remunerated membership: EORTC